[144] Ocular Therapeutix, Inc. SEC Filing

Rhea-AI Filing Summary

Ocular Therapeutix filed a Form 144 notifying of a proposed sale of 3,063 shares of its common stock that were acquired through restricted stock vesting on 08/22/2025. The filing lists the intended sale date as 08/25/2025, an aggregate market value of $36,882.81, and indicates the shares trade on NASDAQ. The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services in New York.

The filer represents no material nonpublic information is known and notes no sales by the person in the past three months. Certain identifying fields (for example, filer CIK and filer name) are not populated in the provided content.

Positive

• Required sale details disclosed including number of shares, acquisition method, intended sale date, and aggregate value
• Broker identified (Morgan Stanley Smith Barney LLC), supporting standard execution

Negative

• Filer identification fields not shown in the provided content (CIK and filer name are blank in this extract)
• Insider sale of vested restricted stock (could be interpreted by some market participants, though amount is small)

Insights

Securities Analyst

TL;DR: Routine insider sale notice for a small block of vested restricted shares; not material to company valuation.

The filing reports a planned sale of 3,063 shares valued at $36,882.81, representing a de minimis portion of the issuer's outstanding shares (173,995,221 reported outstanding). The acquisition was via restricted stock vesting on 08/22/2025, with a target sale date three days later. From a market-impact perspective, the size and timing indicate this is a routine disposal following vesting rather than a significant liquidity event. The disclosure of the executing broker supports standard market execution.

Compliance/Risk Analyst

TL;DR: Filing appears to follow Rule 144 mechanics, but some identifying fields are unpopulated in the provided extract.

The notice contains required elements: class of security, acquisition date and nature (restricted stock vesting), number of shares to be sold, aggregate value, intended sale date, and broker information. The filer affirms lack of undisclosed material information and reports no sales in the prior three months. However, the provided content omits explicit filer identification details (CIK and filer name), which are necessary for clear public record linking; ensure the complete filing includes those fields.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3063	36882.81	173995221	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2025	Restricted stock vesting under a registered plan	Issuer			3063	08/22/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Ocular Therapeutix (OCUL) disclose in this Form 144?

The filing notifies a proposed sale of 3,063 common shares acquired via restricted stock vesting on 08/22/2025, with an intended sale date of 08/25/2025.

How much are the shares worth according to the filing?

The aggregate market value reported is $36,882.81 for the 3,063 shares.

Which broker will handle the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC Executive Financial Services located at 1 New York Plaza, 8th Floor, New York, NY.

Were there any other sales by this person in the past three months?

The filing reports Nothing to Report for securities sold during the past three months by the person for whose account the sale is to be made.

Is there any indication of undisclosed material information in the filing?

The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.